GLP-1 receptor agonists × quality of life & behaviour

TrialObesity facts2020

Effects of Dietary Self-Monitoring, Physical Activity, Liraglutide 3.0 mg, and Placebo on Weight Loss in the SCALE IBT Trial.

Jena S Tronieri et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 282 people · 2020

Randomised comparison

Probably lowered quality of life & behaviour

−6.50percentage points−10.2 to −2.90

As reported

difference −6.5 %, 95% CI −10.2 to −2.90

Not counted

Probably lowered quality of life & behaviour

−7.20percentage points−10.4 to −4.00

As reported

difference −7.2 %, 95% CI −10.4 to −4.00

Two numbers in the abstract

the abstract, start to end

with estimated weight changes of -7.2% (95% CI -10.4 to -4.0; p <

predicted an additional weight loss of -6.5% (95% CI -10.2 to -2.9; p =

← favours treatmentfavours comparator →
could be chance
Quality of life & behaviour
−7.2−10.4 to −4.00
Quality of life & behaviour
−6.5−10.2 to −2.90
GLP-1 receptor agonistsDiet, exercise & lifestyleQuality of life & behaviour

GLP-1 receptor agonists × quality of life & behaviourhelps?mixed

unlikelylikely
0.440.50 without it
← favours comparatorfavours treatment →
this papermore certainless certain
1 / 6

12 papers cite it

2020
2021
2022
2023
2024
2025
2026
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 33197917